TopoTarget Announces Allowance of Valproic Acid Patent in Europe covering Savicol™

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen 
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

To OMX Nordic Exchange Copenhagen
Announcement No. 10-08 / Copenhagen, April 2, 2008

TopoTarget Announces Allowance of Valproic Acid Patent in Europe Covering
Savicol™ 

Copenhagen, Denmark - April 2, 2008 - TopoTarget A/S (OMX:  TOPO) today
announced that a patent related to the histone deacetylase inhibitor valproic
acid (VPA), the active ingredient of TopoTarget´s drug product Savicol™, has
been allowed in Europe. Corresponding applications are pending in major
territories including the US, Japan, India, China, Mexico and Brazil. 

The allowed application EP04 010 333 covers TopoTarget's novel formulation of
VPA now called Savicol™. This is a tablet formulation with biphasic release
kinetics i.e. some of the drug is released quickly and some slowly in order to
give high and constant therapeutic drug levels over a long time period. The
allowed application has broad claims to VPA tablets with biphasic release
kinetics and to their use in diverse indications such as Familial Adenomatous
Polyposis and cancer. 

Savicol™ is based on a novel and proprietary, orally available formulation of
VPA. VPA is a molecule which acts as an HDAC inhibitor, preferentially for HDAC
class I isoenzymes, which are involved in excessive cell proliferation and
tumorigenesis. Furthermore, the Savicol™ formulation allows a specific
pharmacokinetic release pattern of VPA expected to effectively inhibit these
target enzymes. The HDAC inhibitory effect of VPA has already been demonstrated
in Phase I trials on the basis of biomarker monitoring of histone acetylation.
Pivotal phase II trials are ongoing and data from these trials are expected
during 2008. 

Savicol™ was granted Orphan Drug status for Familial Adenomatous Polyposis in
Europe in 2004 and in the US in 2005. 

“This formulation principle now utilized in TopoTarget´s drug product Savicol™
distinguishes it from any other VPA containing medication available and thus
represents a unique advantage,” said Peter Buhl Jensen, Chief Executive Officer
of TopoTarget A/S. “This patent is part of TopoTarget's strategy to vigorously
protect our product portfolio with a robust patent estate”. 

Today's news does not change TopoTarget's full-year financial guidance.

TopoTarget A/S

	
For further information, please contact:

Ulla Hald Buhl 	Telephone	+45 39 17 83 92
Director IR & Communications	Mobile	+45 21 70 10 49
Background information

About Savicol™
Savicol™ is based on a novel and proprietary, orally available formulation of
valproic acid (VPA). VPA is a molecule which acts as an HDAC inhibitor,
preferentially for HDAC class I isoenzymes, which are involved in excessive
cell proliferation and tumourigenesis. Furthermore, the Savicol™ formulation
allows a specific pharmacokinetic release pattern of valproic acid expected to
effectively inhibit these target enzymes. The HDAC inhibitory effect of VPA has
already been demonstrated in Phase I trials on the basis of biomarker
monitoring of histone acetylation. 
Savicol™ was granted Orphan Drug status for the FAP indication in Europe in
2004 and in the US in 2005. 
About TopoTarget 
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding
''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and nine drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene®/Totect™ were approved by EMEA in 2006 and the FDA in 2007 and is
TopoTarget's first product on the market. For more information, please refer to
www.topotarget.com. 

TopoTarget Safe Harbour Statement 
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements.  TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.